Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-08-14 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于公司2024年半年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2024 half-year profit distribution plan. It references the 2024 half-year financial report (unaudited) but does not contain the full financial statements or detailed financial analysis itself. The document mainly discusses the proposed dividend payout, board and supervisory committee approvals, and legal compliance related to the profit distribution plan. It is a formal announcement of a dividend plan rather than a full interim or annual financial report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters and it is not merely announcing the publication of a report but announcing a dividend plan based on interim results.
2024-08-14 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 亿帆医药股份有限公司 regarding the approval of the company's 2024 semi-annual report and related matters such as profit distribution plan, use of raised funds, and asset impairment provisions. It includes voting results and confirms the legality and compliance of the report preparation process. The document is not the semi-annual report itself but a formal announcement of the Supervisory Board's meeting resolutions and approvals related to the interim report and other corporate governance matters. The document length is short (1389 characters) and it does not contain detailed financial statements or substantive financial data, but rather the meeting resolutions and approvals. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and approvals related to the interim report and corporate governance issues, rather than the interim report itself (IR) or a voting result announcement (DVA).
2024-08-14 Chinese
关于2024年上半年计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Yifan Pharmaceutical Co., Ltd. regarding the provision for asset impairment for the first half of 2024. It details the amounts of impairment provisions made for various asset categories such as accounts receivable and inventory, the accounting standards followed, and the impact on the company's financial results. The document includes resolutions from the board of directors, audit committee, and supervisory board approving the impairment provision. The text is about a specific accounting adjustment and its approval, not a full financial report or earnings release. It is a regulatory announcement related to financial disclosures but does not contain comprehensive financial statements or detailed management discussion. The document length is 3390 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-14 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, industry information, and financial indicators for the first half of 2024 (January to June). The document is lengthy (15,000 characters) and includes comprehensive financial statements and analysis, which are characteristic of an Interim / Quarterly Report. It is not a brief announcement or a certification letter, but a full report covering a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-08-14 Chinese
申万宏源证券承销保荐有限责任公司关于亿帆医药股份有限公司变更部分募集资金用途并永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a securities underwriting and sponsorship company regarding the change in the use of funds raised by a company through a non-public stock issuance in 2017. It discusses the original fundraising, the use of funds, changes in investment projects, and the approval process by the board and supervisory committee. The document is focused on the use and management of raised capital, specifically the change in the use of part of the raised funds to permanently supplement working capital. It is not a full annual or interim financial report, nor is it an earnings release or a regulatory filing of a different nature. It is a formal verification and opinion related to capital use and fundraising activities, which fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive content about the fundraising and capital use, not just an announcement of a report publication. Therefore, the classification is CAP with high confidence.
2024-08-14 Chinese
关于变更部分募集资金用途并永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 亿帆医药股份有限公司 regarding the change in the use of part of the funds raised from a 2017 non-public stock issuance. It details the original fundraising, the projects funded, the reasons for changing the use of the remaining funds, and the approval process including board and supervisory opinions. The document is a formal disclosure about the change in the use of raised capital and the permanent supplementation of working capital. It does not contain financial statements or detailed financial results but is a regulatory announcement about capital use changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is about 4955 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2024-08-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.